Indapta Presents NK Cell Therapy Data at SITC 2024
07 Nov 2024 //
BUSINESSWIRE
Indapta G-Nk Plenary Featured: Nyas Cancer Immunotherapy Conference
23 May 2024 //
BUSINESSWIRE
Indapta Awarded $4.5M By CPRIT For NK Cell Therapy
21 May 2024 //
BUSINESSWIRE
Indapta Therapeutics Receives U.S. FDA Fast Track Designation for IDP-023
29 Feb 2024 //
BUSINESSWIRE
Indapta Therapeutics Announces First Patients Treated with IDP-023
11 Jan 2024 //
BUSINESSWIRE
Indapta plans Phase I trial of NK Cell therapy
17 May 2023 //
CLINICAL TRIALS ARENA
Indapta Therapeutics Names Moya Daniels, Senior Vice President
17 Jan 2023 //
BUSINESSWIRE